Company / Operating Income
Aclaris Therapeutics, Inc. Operating Income History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$76.4M
FY2025
5-year range
-$97.4M / -$76.4M
FY2021-FY2025
Trend
+21.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has fluctuated over the past 9 years, ranging from -$97M in FY2024 to -$21M in FY2017.
Based on SEC 10-K filings.
-$76M in FY2025.
Improved from -$90M to -$76M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income increased 21.6% year-over-year.
- Peak operating income was recorded in FY2017.
- Lowest operating income in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$76.4M | +21.6% |
| FY2024 | -$97.4M | -8.5% |
| FY2023 | -$89.7M | +0.1% |
| FY2022 | -$89.9M | -0.1% |
| FY2021 | -$89.7M | -5.8% |
| FY2020 | -$84.8M | -56.0% |
| FY2019 | -$54.4M | +35.9% |
| FY2018 | -$84.8M | -310.2% |
| FY2017 | -$20.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026